Image Ben Hargreaves Market Access Are we entering a new era of blockbuster weight-loss drugs? Has the industry found a new revenue driver in weight-loss treatments? R&D Allogeneic therapies: The future of cancer treatment? Allogeneic therapies could provide an answer to some of the drawbacks of autologous therapies. Patients Zebras, not horses: combatting rare disease via education Elsevier launches open-access journal 'Rare' and short-form videos to educate on rare disease. Oncology Could cancer be the next mRNA breakthrough? mRNA vaccines achieved their first success against COVID-19, but could a cancer target be next? Load more results
Market Access Are we entering a new era of blockbuster weight-loss drugs? Has the industry found a new revenue driver in weight-loss treatments?
R&D Allogeneic therapies: The future of cancer treatment? Allogeneic therapies could provide an answer to some of the drawbacks of autologous therapies.
Patients Zebras, not horses: combatting rare disease via education Elsevier launches open-access journal 'Rare' and short-form videos to educate on rare disease.
Oncology Could cancer be the next mRNA breakthrough? mRNA vaccines achieved their first success against COVID-19, but could a cancer target be next?
News CDC panel votes to scrap hepatitis B birth dose advice CDC advisers vote to overturn decades of US policy and abandon endorsement of universal hepatitis B vaccination for newborns in the US.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
